efgartigimod administration

Phase 3

argenx SE (ARGX)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jan '27

ARGXPhase 3$58.8B

efgartigimod administration Phase 3 Est. Readout

efgartigimod administration• Myasthaenia Gravis30

Jan 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Myasthaenia Gravis

View Full Landscape

Drug Information

Target Indication

Myasthaenia Gravis

Clinical Trial

NCT06765161

Last updated: 8/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ARGX

argenx SE

Biological Products, (No Diagnostic Substances)•Europe•NASDAQ

Related Pipeline

ARGX-113Phase 3

Pemphigus Vulgaris

Efgartigimod PH20 SCPhase 3

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

EFG PH20 SCPhase 3

Active Idiopathic Inflammatory Myopathy

IVIG (Intravenous Immunoglobulin)Phase 3

Multifocal Motor Neuropathy (MMN)

Efgartigimod IVPhase 3

Generalized Myasthenia Gravis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts